Prostate News Archive
12-Apr-2008
Cell Genesys Announces Encouraging Results from Phase 1/2 Trial of GVAX Immunotherapy for Prostate Cancer in Recurrent ... (Centre Daily Times)
Cell Genesys, Inc. (Nasdaq:CEGE) today announced data from a completed Phase 1/2 clinical trial (G-9802) of GVAX immunotherapy for prostate cancer in men with recurrent prostate cancer who had not yet received treatment with hormone replacement therapy following relapse after prostate cancer surgery and/or radiation therapy. Data from the trial, which enrolled 19 patients, indicate that GVAX ... Blocking The Effect Of Inflammation-Causing Cells Lowered Prostate Cancer Cells Invasion (Medical News Today)
Recent studies have suggested an association between chronic inflammation and cancers of the prostate, colon, stomach and liver. Now scientists at Northwestern University Feinberg School of Medicine report success in blocking an early step in metastasis of prostate cancer cells by interrupting the communication between the cancer cells and other cells that promote inflammation. Blocking The Effect Of Inflammation-causing Cells Lowered Prostate Cancer Cells Invasion (Science Daily)
Recent studies have suggested an association between chronic inflammation and cancers of the prostate, colon, stomach and liver. Now scientists report success in blocking an early step in metastasis of prostate cancer cells by interrupting the communication between the cancer cells and other cells that promote inflammation. 3T MRI Plays Significant Role in Detecting Prostate Cancer, Study Says (Newswise)
The use of MRI without endorectal coil can detect prostate cancer and provide undistorted images with diagnostic image quality and accurate tumor localization, according to a recent case report conducted by researchers from The Ohio State University in Columbus, OH.
Back to Prostate News Archive
